Guidelines from the American Diabetes Association and the European Association for the Study of Diabetes recommend GLP-1 medications as preferred agents for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease
However, to date, extensive RCTs have shown no correlation between specific GLP-1 RAs and increased cancer risk
Monitoring recommendations Baseline assessments: Pre-research evaluation should include metabolic panel, lipid profile, thyroid function, and other relevant markers
Use this window to establish eating patterns you can sustain when appetite normalizes
GLP-1s approved for diabetes include Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (oral semaglutide), Trulicity (dulaglutide), and Victoza (liraglutide)
Signs of degradation include changes in color, cloudiness, unusual smell, or a noticeable decrease in effectiveness despite consistent technique